Skip to main content
    H

    Health Catalyst Inc (HCAT)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $1.38
    -0.13 (-8.61%)

    Market Cap: $115.00M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Health Catalyst Inc (HCAT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Health Catalyst (HCAT) trades at 0.4x sales and 0.7x book value. Its P/S of 0.4x is below its 5-year median of 1.4x. Its forward P/E is 10.0x.

    Current Multiples

    Its free cash flow yield is 24.7%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E10.0x
    Price to sales0.4x
    Price to book0.7x
    Price to FCF4.0x
    EV/FCF2.0x
    PEGN/A
    FCF yield24.7%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S0.4x1.4xN/A
    P/B0.7x1.2xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 3 of the 7 year ends shown that have a P/E, its P/E ranged from 25.3x in 2024 to 61.7x in 2023.

    Year endPriceP/EP/SP/B
    2025$2.3934.1x0.5x0.7x
    2024$7.0725.3x1.4x1.2x
    2023$9.2661.7x1.8x1.5x
    2022$10.63N/A2.1x1.4x
    2021$39.62N/A7.8x4.0x
    2020$43.53N/A9.1x6.7x
    2019$34.70N/A1.9x6.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HCAT

    What is HCAT's forward P/E ratio?

    Health Catalyst has a forward P/E ratio of 10.0x.

    Is HCAT stock overvalued?

    GNG's valuation label for HCAT is Undervalued.

    What is HCAT's price to sales ratio?

    Health Catalyst has a price to sales ratio of 0.4x.